2024-04-15 04:25:44 ET
Summary
- Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return.
- The company has key pipeline milestones in 2024, focusing on expanding sales of rare disease drugs and advancing drugs in oncology.
- Despite strong financial results in FY'23, Amgen's valuation is dependent on future growth and managing its significant debt.
"Science Lessons" is a famous book by Gordon Binder, the now 89 year-old who led Amgen ( AMGN ) as CEO from 1988-2000 and CFO from 1982-1988. It discusses Amgen's growth as a biopharmaceutical company, along with the company's core focuses on discovery and science in what is an incredibly tough industry....
Read the full article on Seeking Alpha
For further details see:
Amgen: The Giant With An Impressive Pipeline